We’re committed to backing initiatives that bring us closer to delivering effective treatments for people with dementia, that’s why we’ve joined the CAMD.
We need to learn from recent failings in clinical trials and inform research feeding back into the early drug development pipeline.
Why would we need to diagnose the disease before those symptoms appeared? The answer lies in the search for new treatments.
We look at the most promising developments in the treatments of Alzheimer’s disease.
Alzheimer’s Research UK’s Director of Research Dr Eric Karran spoke recently about his hopes for the development of new Alzheimer’s treatments and dementia research.
Dr Laura Phipps blogs on how you can help with the research effort in dementia.
In this short piece on the placebo effect I’m going to describe why we need clinical trials to develop new Alzheimer’s treatments. And cups of tea.
The latest results from the Elan dementia trials have proved one of the more interesting dementia research stories of the summer.
This month we’ll be at the political party conferences urging all parties to continue to back dementia research. With no new drugs since 2003, and those in existence only showing modest efficacy, we desperately need new treatments that can delay the onset, slow the progression and manage the symptoms of dementia.